Technology Area: Immunotherapy
122 Results for 'Immunotherapy'
- Technologies (14)
- Collaborations (2)
- Team (0)
- News (88)
- Pages (0)
- Multimedia (18)
- Publications (0)
- Jobs (0)
- Events (0)
Technologies 14
-
TIB: Tolerance Inducing Biomaterials for Regulatory T Cells
Easily injectable biomaterial technology to induce and localize regulatory T cells to specific tissues and sustain their pro-regenerative activities in tissue regeneration with a focus on musculoskeletal diseases and injuries. -
DoriVac: DNA Origami-Based Vaccines for Combination Immunotherapy
Personalized cancer and infectious disease vaccine platform harnessing DNA nanotechnology to control the co-delivery and co-presentation of tumor antigen and adjuvant ligands to immune cells with nanoscale precision. This approach has potential to trigger enhanced immune responses against tumors and infectious pathogens. -
Metabolically Labeled CAR-T Cells Against Cancer
Through a simple and effective metabolic labeling approach, patient-derived T cells engineered to carry immune-enhancing cytokines on their surfaces could help expand adoptive T cell therapies to treatment of solid tumors and improve blood cancer therapies. -
NodeTX: Growing Lymph Nodes to Treat Cancer
NodeTX is a novel immunotherapy that leverages the human body's innate ability to grow lymph nodes to fight tumors. -
Cellular “Backpacks” to Fight Cancer, Autoimmune Disorders, and More
Macrophages are very malleable immune cells, but that also means that they can be influenced by cancerous tumors and inflammatory processes. Our cellular "backpacks" stick to macrophages and can deliver molecules that keep them in their desired state for cell therapy and more. -
Tunable ECMs for More Effective T cell Therapies
Tunable hydrogels that enhance the efficacies of adoptively transferred immune cells during their manufacturing by mimicking target tissue biomechanics.
Collaborations 2
-
Nucleic Acid Delivery Consortium
An academic-industry consortium focused on the challenge of delivering nucleic acid-based therapies to specific target organs, tissues, and cells. -
i3 Center: Biomaterials to Create T Cell Immunity
Cancer immunologists and biological engineers are developing new biomaterials-based approaches to develop new anti-cancer immunotherapies for treatment-resistant cancers.
News 88
Multimedia 18
-
Video/Animation20-ish Questions with David J. Mooney20-ish Questions shows a different side of Wyss Institute faculty, touching on aspects of their personal life, hobbies, interests, as well as their research. This round follows David J. Mooney, a Founding Core Faculty member and Lead of the Immuno-Materials platform at the Wyss Institute. He is also the Robert P. Pinkas Family Professor of... -
Video/AnimationDavid Mooney on the Mission to Save Lives Through Cancer ResearchDavid Mooney, Core Faculty member of the Wyss Institute and Robert Pinkas Family Professor of Bioengineering in the Harvard School of Engineering and Applied Sciences, discusses training immune cells to recognize and destroy cancer mutations. While current immunotherapies create nearly miraculous cures for some patients, they only work for certain cancers and a fraction of... -
Video/AnimationHow can we train the immune system to fight cancer?The implantable cancer vaccine is a biomaterial that recruits and reprograms a patient’s own immune cells on-site to kill cancer cells. This revolutionary immuno-material technology was tested in a Phase I clinical trial with promising results and is currently licensed by Novartis as an immunotherapy to treat specific tumor types. Credit: Wyss Institute at Harvard... -
Video/AnimationMetabolic T cell Labeling: simple and effective enhancement of therapeutic T cells with immune-stimulating cytokinesThis animation shows how the surface of patient-derived T cells is metabolically labeled with azido-sugar molecules that then can be used to attach immune-enhancing cytokines with the help of click chemistry. The approach could help expand adoptive T cell therapies to treatment of solid tumors. Credit: Wyss Institute at Harvard University
-
Video/AnimationEliminating brain cancer at its source | Natalie Artzi | TEDxMITGlioblastoma is a lethal, aggressive brain cancer with a dismal median overall survival rate of 15 months, a number that has remained unchanged for decades. Treatment for this devastating disease involves surgical resection followed by chemotherapy and radiation therapy; however, tumor recurrence is inevitable as it is impossible to eliminate all tumor cells with current... -
Audio/PodcastImmunoengineering with Dave Mooney – BIOS PodcastWyss Core Faculty member Dave Mooney is a leader in the fields of biomaterials, mechanotransduction, drug delivery, tissue engineering and immunoengineering. He is interested in understanding how cells sense signals in their environment and how this alters cell behavior. His laboratory develops biomaterials that exploit these signals to regulate specific cells and their function. They...